Charli Smardon

Title: **Innovator Spotlight: Charli Smardon - A Pioneer in Oral Vaccine Technology**

Introduction

Charli Smardon, based in Wiltshire, GB, is a remarkable inventor recognized for his contributions in the field of oral vaccine technology. With three patents to his name, Charli's innovations are pivotal in advancing immunization methods and improving vaccine delivery systems.

Latest Patents

Charli’s most notable inventions include two patents related to oral dispersible vaccines comprising virosomes. These patents focus on oral vaccine dosage forms that utilize lipid-based vesicles, such as virosomes and liposomes, designed to harbor immunogenic substances. The innovative dosage forms and the accompanying processes allow for the creation of solid dosage forms that maintain physical robustness and integrity of both particles and antigens. Charli’s work in this area highlights the potential for developing freeze-dried sublingual dosage forms, which can significantly enhance vaccine stability and effectiveness.

Career Highlights

Throughout his career, Charli has made significant strides in the pharmaceutical sector, working with prominent companies such as Catalent UK Swindon, Zydis Limited, and Mymetics Corporation. His experiences in these organizations have enabled him to harness his expertise in formulation and vaccine technologies, resulting in impactful innovations that aim to improve public health.

Collaborations

Charli Smardon has collaborated with notable professionals in his field, including Yik Teng Wong and Khojasteh Shirkhani. These partnerships have been essential in enhancing his research and development efforts, driving progress in vaccine engineering and delivery systems.

Conclusion

In summary, Charli Smardon stands out as a notable inventor in the realm of oral vaccines. His dedication to innovation has not only reshaped how vaccines can be administered but also promises to lead to safer and more effective immunization strategies. With ongoing research and collaboration, Charli continues to pave the way for future advancements in vaccine technology.